Biotech

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs By Wayne Schnarr When I started my job in 1989 as a lobbyist for the Canadian generic drug industry, I thought that my job would be accumulating and organizing facts in a logical manner to present to consumer groups, governments ...

Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala

Annual Award Recognizes the Most Significant Contributor to Canada’s Innovative Healthcare Industry  TORONTO, February 12, 2018 – Bloom Burton & Co. (“Bloom Burton”) is thrilled to announce the 2018 Bloom Burton Award Gala, to be held at the Four Seasons Hotel in Toronto, Ontario, Canada ...

Top 6 issues facing the biotechnology industry

This article was originally published at https://www.drugpatentwatch.com/blog/top-6-issues-facing-biotechnology-industry/ For the last century, drug development consisted of tiny-molecule treatments focused at mass audience. It worked for some patients while it didn’t for the rest. In some cases, ...

Bulls Stomp On The Gas, Biotechs Explode

Market Recap for Friday, January 26, 2018 The bears were absolutely stymied on Friday as the major indices surged to unprecedented levels.  Despite the very overbought conditions that have persisted on many indices for four months now, bulls dominated the action and show no signs of letting up. ...

Oncolytics Biotech has 194% upside, Paradigm Capital says

Its stock has been on an extended upswing since last July, but Paradigm Capital analyst Rahul Sarugaser thinks there is plenty of upside left in Oncolytics Biotech (TSX:ONC). Oncolytics Biotech recently published data that demonstrated early signs that its proprietary REO drug may be effective in ...

Q4 & Annual 2017 Share Price Performance – Part 3

            Tier 2 Canadian Healthcare Companies: A Few Outperformers, Balanced with Usual High Volatility In this blog, I am going to comment on the Q4 and annual 2017 share price performance of the group of 64 companies with share prices of between $0.10 and $0.99 to start 2017 (excludes c ...

Three Canadian biotech stock picks from Next Edge Capital’s Eden Rahim

Canada’s biotech sector has seen its ups and downs over recent years but there are still plenty of good companies to be bullish about, if you know where to find them. Cantech Letter spoke to veteran biotech portfolio manager Eden Rahim from Next Edge Capital and got the lowdown on three stocks t ...

These three Canadian biotech stocks are buys, analysts say

Prometic Life Sciences CEO Pierre Laurin Will this be a banner year for Canada’s Life Sciences sector? After a poor showing in 2016, last year certainly saw a number of success stories, with companies like Fennec Pharma, Aptose Biosciences and Oncolytics Biotech all coming out as top performers. ...

December 22, 2017

Manulife has announced a 2.9-billion hit for 17Q4. Management must be distraught that such an important development had to be announced after the market closed for the Christmas holiday – with no time to publish a press release on their website, darn it! It only made it to Newswire – so I’ll ...

2018 Charity 100: Grades

.best-stocks-2017-hed{margin-bottom:1em;max-width:100%}@media (max-width: 991px){a.flex-item{width:93%}}@media (min-width: 992px){.best-stocks-2017-links{display:flex;flex-direction:row;flex-wrap:nowrap;justify-content:space-between;align-content:space-around;align-items:flex-start}}a.flex-item{dis ...